COLUMBUS 5-Year Update: A Randomized, Open-Label, Phase III Trial of Encorafenib Plus Binimetinib Versus Vemurafenib or Encorafenib in Patients With BRAF V600-Mutant Melanoma.
Reinhard DummerKeith T FlahertyCaroline RobertAna M AranceJan Willem B de GrootClaus GarbeHelen J GogasRalf GutzmerIvana KrajsováGabriella LiszkayCarmen LoquaiMario MandalaDirk SchadendorfNaoya YamazakiAlessandra di PietroJean Cantey-KiserMichelle EdwardsPaolo Antonio AsciertoPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022)
V600-mutant melanoma.